Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 2/20 | 0.35 |
| ▸ | PPP5C | P53041 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18102782 | 1.00 | SMN1; SMN2 (0.35) | SMN1; SMN2GBA1PPP5CTSHRCYP1A2 | |
| SCHEMBL17266376 | 1.00 | SMN1; SMN2 (0.35) | SMN1; SMN2GBA1PPP5CTSHRCYP1A2 | |
| SCHEMBL14017758 | 1.00 | SMN1; SMN2 (0.35) | SMN1; SMN2GBA1PPP5CTSHRCYP1A2 | |
| SCHEMBL10151543 | 0.96 | CYP1A2 (0.35) | SMN1; SMN2GBA1PPP5CTSHRCYP1A2 | |
| SCHEMBL10160046 | 0.96 | CYP1A2 (0.35) | SMN1; SMN2GBA1PPP5CTSHRCYP1A2 | |
| SCHEMBL14018563 | 0.96 | CYP1A2 (0.35) | SMN1; SMN2GBA1PPP5CTSHRCYP1A2 | |
| SCHEMBL20995941 | 0.87 | SMN1; SMN2 (0.40) | SMN1; SMN2GBA1PPP5CTSHRCYP1A2 | |
| SCHEMBL10304571 | 0.85 | GBA1 (0.41) | SMN1; SMN2GBA1PPP5CTSHR | |
| SCHEMBL15033397 | 0.83 | CYP19A1 (0.33) | CYP1A2 | |
| SCHEMBL15424813 | 0.83 | CYP19A1 (0.33) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170158614-A1 | AUTOMATED SYNTHESIS OF SMALL MOLECULES USING CHIRAL, NON-RACEMIC BORONATES | NATIONAL SCIENCE FOUNDATION | 2017-06-08 | — | — | US | disclosed |
| US-20160280721-A1 | CROSS-COUPLING OF UNACTIVATED SECONDARY BORONIC ACIDS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2016-09-29 | — | — | US | disclosed |
| US-9388131-B2 | Automated synthesis of small molecules using chiral, non-racemic boronates | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-07-12 | — | — | US | disclosed |
| US-20150329567-A1 | Automated Synthesis of Small Molecules Using Chiral, Non-Racemic Boronates | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2015-11-19 | — | — | US | disclosed |
| US-9012658-B2 | Automated synthesis of small molecules using chiral, non-racemic boronates | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329567-A1 | Automated Synthesis of Small Molecules Using Chiral, Non-Racemic Boronates | BTD, POLL, POLR1A | SMN1; SMN2 2506/4885GBA1 480/4885PPP5C 1954/4885 |
| US-20160280721-A1 | CROSS-COUPLING OF UNACTIVATED SECONDARY BORONIC ACIDS | BOLA2; BOLA2B, BLVRB, CD79B | SMN1; SMN2 2676/4885GBA1 1808/4885PPP5C 4356/4885 |
| US-20170158614-A1 | AUTOMATED SYNTHESIS OF SMALL MOLECULES USING CHIRAL, NON-RACEMIC BORONATES | BTD, POLL, POLR1A | SMN1; SMN2 2506/4885GBA1 480/4885PPP5C 1954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.